Poison oak, ivy, sumac dermatitis - Revision history

Danbot: Danbot moved page Poison Oak, Ivy, Sumac dermatitis to Poison oak, ivy, sumac dermatitis without leaving a redirect: Naming convention: first word capitalized, subsequent words lowercase

2026-03-22T05:33:46Z

Danbot moved page Poison Oak, Ivy, Sumac dermatitis to Poison oak, ivy, sumac dermatitis without leaving a redirect: Naming convention: first word capitalized, subsequent words lowercase

← Older revision	Revision as of 05:33, 22 March 2026
(No difference)

Rossdonaldson1: /* Video */

2024-04-17T20:13:23Z

Video

← Older revision		Revision as of 20:13, 17 April 2024
Line 75:		Line 75:
	*[[Rashes]]		*[[Rashes]]
	*[[Contact dermatitis]]		*[[Contact dermatitis]]

	~~==Video==~~
	~~{{#widget:YouTube\|id=eqz9QsoqjTc}}~~

	==References==		==References==

Rossdonaldson1: /* Clinical Features */

2023-09-13T17:37:09Z

Clinical Features

← Older revision		Revision as of 17:37, 13 September 2023
Line 27:		Line 27:
	[[File:PoisonIvyOakSumac.jpeg\|thumbnail\|Urushiol induced rash]]		[[File:PoisonIvyOakSumac.jpeg\|thumbnail\|Urushiol induced rash]]
	[[File:Urushiol induced contact dermatitis.jpg\|thumb\|Urushiol induced contact dermatitis]]		[[File:Urushiol induced contact dermatitis.jpg\|thumb\|Urushiol induced contact dermatitis]]
			[[File:Severe allergic reaction to urushiol (poison oak) 4 days after exposure.jpg\|thumb\|Contact dermatitis from poison oak exposure (Day 4).]]
	*Previous exposure leads to sensitization and earlier symptoms		*Previous exposure leads to sensitization and earlier symptoms
	**1-2 days for previous sensitizations and 10-14 days for first contact		**1-2 days for previous sensitizations and 10-14 days for first contact

Rossdonaldson1: /* Background */

2020-09-10T22:47:04Z

Background

← Older revision		Revision as of 22:47, 10 September 2020
Line 1:		Line 1:
	==Background==		==Background==
			[[File:Poison-ivy-oak-sumac.jpg\|thumb\|]]
	[[File:Poison Ivy in Perrot State Park.jpg\|thumb\|Poison Ivy]]		[[File:Poison Ivy in Perrot State Park.jpg\|thumb\|Poison Ivy]]
	*Type of [[Contact dermatitis\|contact dermatitis]]		*Type of [[Contact dermatitis\|contact dermatitis]]
Line 20:		Line 21:
	*2 opposing leaflets single terminal leaf		*2 opposing leaflets single terminal leaf
	\|}		\|}
	~~[[File:Poison-ivy-oak-sumac.jpg\|400px]]~~

	{{Dermatitis types}}		{{Dermatitis types}}

Rossdonaldson1: /* Background */

2020-09-10T22:46:33Z

Background

← Older revision		Revision as of 22:46, 10 September 2020
Line 21:		Line 21:
	\|}		\|}
	[[File:Poison-ivy-oak-sumac.jpg\|400px]]		[[File:Poison-ivy-oak-sumac.jpg\|400px]]

			{{Dermatitis types}}

	==Clinical Features==		==Clinical Features==

Lyssa1219: /* Symptomatic Treatment */

2020-04-20T19:59:22Z

Symptomatic Treatment

← Older revision		Revision as of 19:59, 20 April 2020
Line 47:		Line 47:
	**Oatmeal baths		**Oatmeal baths
	**Cool, wet compresses		**Cool, wet compresses
			**Ice packs
	**Topical menthol and phenol (calamine lotion) compounds		**Topical menthol and phenol (calamine lotion) compounds
	**Topical astringents under occlusion dressing to dry weeping lesions<ref>Poison ivy dermatitis. Baer RL Cutis. 1990;46(1):34</ref>		**Topical astringents under occlusion dressing to dry weeping lesions<ref>Poison ivy dermatitis. Baer RL Cutis. 1990;46(1):34</ref>

ClaireLewis: /* Not Indicated */

2019-09-14T23:44:49Z

Not Indicated

← Older revision		Revision as of 23:44, 14 September 2019
Line 61:		Line 61:

	===Not Indicated===		===Not Indicated===
	*Topical antihistamines		*Topical [[antihistamines]]
	*Anesthetics containing benzocaine		*Anesthetics containing [[benzocaine]]
	*Antibiotics containing neomycin or bacitracin		*Antibiotics containing [[neomycin]] or [[bacitracin]]

	==Disposition==		==Disposition==

Kxl328: /* Background */

2018-09-01T21:44:30Z

Background

← Older revision		Revision as of 21:44, 1 September 2018
Line 20:		Line 20:
	*2 opposing leaflets single terminal leaf		*2 opposing leaflets single terminal leaf
	\|}		\|}
			[[File:Poison-ivy-oak-sumac.jpg\|400px]]

	==Clinical Features==		==Clinical Features==

Aganapathy: /* Symptomatic Treatment */

2018-01-28T10:02:50Z

Symptomatic Treatment

← Older revision		Revision as of 10:02, 28 January 2018
Line 55:		Line 55:
	*High-potency [[topical corticosteroids]]: e.g. [[clobetasol propionate]] 0.05% cream		*High-potency [[topical corticosteroids]]: e.g. [[clobetasol propionate]] 0.05% cream
	**No evidence that alters course of disease once vesicles established<ref>Vernon HJ, Olsen EA. A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. J Am Acad Dermatol. 1990;23(5 Pt 1):829.</ref>		**No evidence that alters course of disease once vesicles established<ref>Vernon HJ, Olsen EA. A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. J Am Acad Dermatol. 1990;23(5 Pt 1):829.</ref>
	*Systemic [[corticosteroids]]		*Systemic [[corticosteroids]] for severe disease
	**[[prednisone]] taper over 15-20 days: 60mg x 4d then 50mg x 4d then 40 30 20....Use oral steroid for 3wks until skin turns over		**[[prednisone]] taper over 15-20 days: 60mg x 4d then 50mg x 4d then 40 30 20....Use oral steroid for 3wks until skin turns over
	**Standard burst dosing may be too short (with rebound dermatitis common)<ref>Brodell RT, Williams L. Taking the itch out of poison ivy. Are you prescribing the right medication? Postgrad Med. 1999;106(1):69.</ref>		**Standard burst dosing may be too short (with rebound dermatitis common)<ref>Brodell RT, Williams L. Taking the itch out of poison ivy. Are you prescribing the right medication? Postgrad Med. 1999;106(1):69.</ref>

Rossdonaldson1: /* Symptomatic Treatment */

2017-02-14T11:23:57Z

Symptomatic Treatment

← Older revision		Revision as of 11:23, 14 February 2017
Line 53:		Line 53:
	*Oral [[antihistamines]]		*Oral [[antihistamines]]
	**Occasionally used, primarily for sedating effect (itching in poison ivy dermatitis is not caused by histamine release)<ref>Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziski Z, Wankiewicz A, Marks R, Protas-Drozd F, Mikaszewska M. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology. 2002;205(1):40.</ref>		**Occasionally used, primarily for sedating effect (itching in poison ivy dermatitis is not caused by histamine release)<ref>Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziski Z, Wankiewicz A, Marks R, Protas-Drozd F, Mikaszewska M. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology. 2002;205(1):40.</ref>
	*High-potency [[topical corticosteroids]]: e.g. clobetasol propionate 0.05% cream		*High-potency [[topical corticosteroids]]: e.g. [[clobetasol propionate]] 0.05% cream
	**No evidence that alters course of disease once vesicles established<ref>Vernon HJ, Olsen EA. A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. J Am Acad Dermatol. 1990;23(5 Pt 1):829.</ref>		**No evidence that alters course of disease once vesicles established<ref>Vernon HJ, Olsen EA. A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. J Am Acad Dermatol. 1990;23(5 Pt 1):829.</ref>
	*Systemic [[corticosteroids]]		*Systemic [[corticosteroids]]